<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>The CRISPR-based drug development platforms market capitalizes on the growing demand for precision medicine and gene editing advancements, especially in oncology. Opportunities lie in enhanced drug discovery, rising investments, strategic collaborations, and overcoming technical and regulatory challenges to expand therapeutic applications.Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6249373/crispr-based-drug-development-platforms-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=79sfp8&amp;utm_campaign=2292521+-+Global+CRISPR-Based+Drug+Development+Platforms+Market+to+Reach+USD+0.79+Billion+by+2031%3a+Precision+Medicine+and+Gene+Therapy+Drive+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Crispr-Based Drug Development Platforms Market - Strategic Insights and Forecasts (2026-2031)">"Crispr-Based Drug Development Platforms Market - Strategic Insights and Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. The CRISPR-Based Drug Development Platforms market is forecast to grow at a CAGR of 11.4%, reaching USD 0.79 billion in 2031 from USD 0.46 billion in 2026. The global CRISPR-based drug development platforms market is positioned at the forefront of precision medicine and next-generation therapeutics. These platforms enable targeted gene editing, accelerating drug discovery and development processes across multiple therapeutic areas. The market is driven by rapid advancements in genome editing technologies, increasing demand for personalized medicine, and the expansion of gene therapy pipelines. Pharmaceutical and biotechnology companies are increasingly adopting CRISPR-based platforms to improve drug development efficiency, reduce timelines, and enhance treatment specificity. Growing investments in biotechnology research and supportive regulatory frameworks are further strengthening the market outlook. Market Drivers A primary driver is the rising focus on precision medicine and targeted therapies. CRISPR technology enables precise modification of DNA sequences, allowing the development of highly specific treatments for genetic disorders, cancer, and infectious diseases. This capability significantly improves therapeutic outcomes and reduces off-target effects, making it a preferred platform for modern drug discovery. Technological advancements such as base editing, prime editing, and epigenome editing are further accelerating market growth. These innovations enhance editing accuracy and expand the range of therapeutic applications. Improved delivery systems are also increasing the efficiency of gene editing processes, supporting broader adoption across research and clinical settings. Additionally, increasing research funding and strategic collaborations between biotechnology firms and academic institutions are driving innovation. Expanding clinical pipelines for gene therapies and rising demand for efficient drug discovery platforms are reinforcing long-term market expansion. Market Restraints Despite strong growth potential, the market faces challenges related to technical complexity and high development costs. CRISPR-based drug development requires advanced infrastructure, specialized expertise, and extensive validation processes, which increase overall costs and limit accessibility for smaller organizations. Regulatory uncertainty also acts as a constraint. Gene editing technologies are subject to strict regulatory scrutiny due to ethical concerns and safety considerations. Approval processes can be lengthy and complex, delaying commercialization. Off-target effects and safety concerns remain critical challenges. Although advancements have improved precision, unintended genetic modifications still pose risks, requiring continuous research and validation. Technology and Segment Insights The market is segmented by product, technology, application, and geography. By technology, CRISPR-Cas9 remains the dominant platform due to its efficiency, cost-effectiveness, and widespread adoption in research and drug development. Emerging technologies such as base editing and prime editing are gaining traction due to their enhanced precision and reduced risk of unintended mutations. In terms of application, oncology represents the largest segment, driven by the growing use of gene editing in cancer treatment development. Other key application areas include genetic disorders, infectious diseases, and rare conditions, reflecting the broad therapeutic potential of CRISPR platforms. End-users include pharmaceutical and biotechnology companies, academic research institutes, and contract research organizations. Pharmaceutical companies account for a significant share due to high investment in drug discovery and clinical development. Competitive and Strategic Outlook The competitive landscape is characterized by the presence of specialized biotechnology companies focusing on innovation and pipeline expansion. Key players include CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, Beam Therapeutics, and Mammoth Biosciences. Strategic initiatives include partnerships, licensing agreements, and investments in advanced gene editing technologies. Companies are also focusing on improving delivery mechanisms and reducing off-target effects to enhance clinical success rates. Expansion of clinical trials and commercialization efforts are key priorities for market participants. Conclusion The global CRISPR-based drug development platforms market is expected to witness steady growth, supported by advancements in gene editing technologies and increasing demand for precision medicine. While regulatory challenges, high costs, and safety concerns persist, continuous innovation and expanding therapeutic applications will drive long-term market development. Key Benefits of this Report <ul><li>Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.</li><li>Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.</li><li>Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.</li><li>Actionable Recommendations: Support strategic decisions to unlock new revenue streams.</li><li>Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.</li></ul> What Businesses Use Our Reports For Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence. Report Coverage <ul><li>Historical data from 2021 to 2025 and forecast data from 2026 to 2031</li><li>Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis</li><li>Competitive positioning, strategies, and market share evaluation</li><li>Revenue growth and forecast assessment across segments and regions</li><li>Company profiling including strategies, products, financials, and key developments</li></ul> Key Topics Covered: 1. EXECUTIVE SUMMARY 2. MARKET SNAPSHOT 2.1. Market Overview 2.2. Market Definition 2.3. Scope of the Study 2.4. Market Segmentation 3. BUSINESS LANDSCAPE 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 3.4. Porter's Five Forces Analysis 3.5. Industry Value Chain Analysis 3.6. Policies and Regulations 3.7. Strategic Recommendations 4. TECHNOLOGICAL OUTLOOK 5. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY PRODUCT 5.1. Introduction 5.2. CRISPR Libraries 5.3. CRISPR Kits &amp; Reagents 5.4. CRISPR Enzymes (Cas Proteins) 5.5. Guide RNA (gRNA) Design Tools 5.6. Delivery Systems 5.7. Cell Lines &amp; Engineering Services 5.8. Software &amp; Bioinformatics Platforms 6. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY TECHNOLOGY 6.1. Introduction 6.2. CRISPR-Cas9 6.3. CRISPR-Cas12 6.4. CRISPR-Cas13 6.5. Base Editing 6.6. Prime Editing 6.7. Epigenome Editing 7. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY APPLICATION 7.1. Introduction 7.2. Drug Discovery &amp; Development 7.3. Functional Genomics 7.4. Disease Modeling 7.5. Target Identification &amp; Validation 7.6. Cell Line Engineering 8. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY GEOGRAPHY 8.1. Introduction 8.2. North America 8.2.1. USA 8.2.2. Canada 8.2.3. Mexico 8.3. South America 8.3.1. Brazil 8.3.2. Argentina 8.3.3. Others 8.4. Europe 8.4.1. United Kingdom 8.4.2. Germany 8.4.3. France 8.4.4. Spain 8.4.5. Others 8.5. Middle East and Africa 8.5.1. Saudi Arabia 8.5.2. UAE 8.5.3. Others 8.6. Asia Pacific 8.6.1. China 8.6.2. India 8.6.3. Japan 8.6.4. South Korea 8.6.5. Indonesia 8.6.6. Thailand 8.6.7. Others 9. COMPETITIVE ENVIRONMENT AND ANALYSIS 9.1. Major Players and Strategy Analysis 9.2. Market Share Analysis 9.3. Mergers, Acquisitions, Agreements, and Collaborations 9.4. Competitive Dashboard 10. COMPANY PROFILES 10.1. CRISPR Therapeutics 10.2. Intellia Therapeutics 10.3. Editas Medicine 10.4. Beam Therapeutics 10.5. Mammoth Biosciences 10.6. Caribou Biosciences 10.7. Synthego 10.8. Lonza Group 10.9. Thermo Fisher Scientific 10.10. Merck KGaA 10.11. Takara Bio Inc. 11. APPENDIX 11.1. Currency 11.2. Assumptions 11.3. Base and Forecast Years Timeline 11.4. Key benefits for the stakeholders 11.5. Research Methodology 11.6. Abbreviations Companies Featured <ul><li>CRISPR Therapeutics</li><li>Intellia Therapeutics</li><li>Editas Medicine</li><li>Beam Therapeutics</li><li>Mammoth Biosciences</li><li>Caribou Biosciences</li><li>Synthego</li><li>Lonza Group</li><li>Thermo Fisher Scientific</li><li>Merck KGaA</li><li>Takara Bio Inc.</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6249373/crispr-based-drug-development-platforms-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=79sfp8&amp;utm_campaign=2292521+-+Global+CRISPR-Based+Drug+Development+Platforms+Market+to+Reach+USD+0.79+Billion+by+2031%3a+Precision+Medicine+and+Gene+Therapy+Drive+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/46vkko</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MDM3YTNmYjUtOWY0ZC00MGE3LWExZTEtYWFlNWMzYjdiYWMzLTEwMjY3MzctMjAyNi0wNy0wMy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn